ARTICLE | Clinical News
Lotronex alosetron selective 5-HT3 antagonist regulatory update
February 14, 2000 8:00 AM UTC
The FDA granted marketing approval for Lotronex to treat women with irritable bowel syndrome (IBS) with symptoms of abdominal pain and discomfort and diarrhea. Product launch is expected mid-March. ...